Omega Diagnostics (ODX.L) said that its technology partner, Mologic Ltd, has filed its submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization for its rapid point-of-care COVID-19 antigen test, for use under both the Omega's VISITECT brand and Global Access Diagnostics brand. The company will provide a further update on the process in due course.
For comments and feedback: editorial@rttnews.com